Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis
- 12 January 2024
- journal article
- research article
- Published by Springer Nature in Quality of Life Research
- Vol. 33 (5) , 1233-1240
Abstract
Purpose This study aimed to estimate minimal clinically important difference (MCID) values for the World Health Organization Quality of Life Brief version (WHOQOL-BREF) among adults with neurofibromatosis (NF). An MCID is needed to demonstrate clinical meaningfulness of interventions for NF. Methods We estimated MCID for the WHOQOL-BREF: the quality of life (QoL) measure recommended by the Response Evaluation in Neurofibromatosis and Schwannomatosis International Collaboration. We used data from 228 clinical trial participants with NF type 1, NF type 2-related schwannomatosis, or schwannomatosis (SCHWN) who completed 10 weeks of a virtual group mind–body program targeting resiliency or a time- and attention-matched control. Following established guidelines, we estimated MCIDs using both anchor-based and distribution-based methods for physical, psychological, social relationships, and environmental domains of the WHOQOL-BREF. Results MCID results varied across method and QoL domain. Three anchor-based methods, average change (AC), change difference (CD), and regression (REG), yielded the most consistent and comparable MCID across QoL domains. Based on these methods, we recommend ranges for each QoL domain: Physical QoL (3.9–7.3), Psychological QoL (4.7–8.1), Social QoL (2.6–5.9), and Environmental QoL (4.1–6.6). Conclusion Establishing a rigorous MCID for QoL in NF is a critical step toward evaluating meaningful change in response to psychosocial interventions.Keywords
Funding Information
- U.S. Department of War (W81XWH-17-1-0121)
This publication has 24 references indexed in Scilit:
- Minimal Clinically Important Differences in Quality of Life Scores of Oral Cavity and Oropharynx Cancer PatientsAnnals of Surgical Oncology, 2014
- Advances in the treatment of neurofibromatosis-associated tumoursNature Reviews Clinical Oncology, 2013
- Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literatureJournal of Neuro-Oncology, 2013
- Assessment of the minimum clinically important difference in pain, disability, and quality of life after anterior cervical discectomy and fusionJournal of Neurosurgery: Spine, 2013
- The minimal clinical important difference in the World Health Organization Quality of Life instrument—100Supportive Care in Cancer, 2012
- Emotional functioning of patients with neurofibromatosis tumor suppressor syndromeGenetics in Medicine, 2012
- The Pathoetiology of Neurofibromatosis 1The American Journal of Pathology, 2011
- ROCR: visualizing classifier performance in RBioinformatics, 2005
- Epidemiology of neurofibromatosis type 1American Journal of Medical Genetics, 1999
- Measurement of health statusControlled Clinical Trials, 1989